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LMP-420, a Small Molecular Inhibitor of TNF-␣, Prolongs Islet
Allograft Survival by Induction of Suppressor of Cytokine Signaling-1:
Synergistic Effect With Cyclosporin-A
Nataraju Angaswamy,* Naohiko Fukami,* Venkataswarup Tiriveedhi,*
George J. Cianciolo,† and T. Mohanakumar*‡
*Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA
†Department of Pathology, Duke University Medical Center, Durham, NC, USA
‡Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA

Inflammatory insults following islet transplantation (ITx) hinders engraftment and long-term function of the
transplanted (Tx) islets. Using a murine model of ITx, we determined the role of LMP-420, a novel TNF-α
inhibitor, both individually and in combination with the immunosuppressant cyclosporine A (CSA) in islet
engraftment and survival. Diabetic C57BL/6 mice were Tx with 500 BALB/c islets under the kidney capsule.
Four cohorts were used: LMP-420 only, CSA only, combination of LMP-420 and CSA (LMP+CSA), and
control (n = 12 per cohort). Serial monitoring of blood glucose levels revealed that LMP+CSA (35 ± 5 days)
prolonged stable blood insulin levels compared to control (6 ± 4 days). Immunohistology demonstrated that
coadministration (LMP+CSA) results in a significant decrease in CD8+ T-cell infiltration (LMP+CSA: 31 ±
18 vs. control: 224 ± 51 cells, p < 0.001). Serum cytokine analysis revealed that LMP-420 administration
resulted in an increase in the anti-inflammatory cytokine IL-10 (2.5-fold), and a decrease in TNF-α (threefold) with no change in IL-2. However, coadministration resulted in a marked decrease in both IL-2 and
TNF-α (threefold) along with increase in IL-10 (threefold). Coadministration also demonstrated increase of
antiapoptotic SOCS-1 and Mn-SOD expression and significant reduction of donor-specific antibodies (p <
0.005). In conclusion, LMP-420 administration with CSA results in the upregulation of anti-inflammatory
and antiapoptotic mechanisms which facilitate islet allograft engraftment and survival.
Key words: LMP-420; Cyclosporin A; Islet transplantation; Type 1 diabetes mellitus;
Tumor necrosis factor-α (TNF-α)

INTRODUCTION

anoxia (42,43,45). This initial insult, resulting from a
proinflammatory milieu, predisposes to alloimmuneand autoimmune-mediated damage of the transplanted
islets (14). Therefore, one of the immediate goals in ITx
is to identify novel strategies to prevent early damage of
these islets.
Among the factors that limit islet graft survival are
inflammatory cytokines, mainly interleukin-1β (IL-1β),
interferon-γ (IFN-γ), and tumor necrosis factor-α (TNFα), which are released by the infiltrating mononuclear
cells (7). TNF-α inhibitors have proven efficacious
towards the treatment and modulation of inflammatory
and autoimmune responses in diseases such as rheumatoid arthritis and psoriasis (44). LMP-420 is a novel
anti-inflammatory purine nucleobase analogue that transcriptionally inhibits TNF-α production (18). LMP-420
is noncytotoxic to TNF-α-producing cells and does not

Type 1 diabetes mellitus (T1DM) is an autoimmune
disease characterized by the destruction of insulinproducing β-islets of the pancreas (41). Parenteral insulin administration still remains the major therapeutic
strategy for treatment of patients with T1DM (31). However, this approach leads to long-term complications
such as diabetic retinopathy, nephropathy, neuropathy,
and macrovascular disease (30). Islet transplantation
(ITx) has been proposed to be an effective treatment to
achieve sustained blood glucose levels in T1DM
patients. However, even with the use of immunosuppressive agents, the long-term success of islet allografts still
remains poor with <10% 5-year survival (21,42). One of
the major reasons for loss of islet function immediately
posttransplant is inflammation caused by ischemia and
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bind to or interfere with the activity of preformed TNFα (28). In addition, studies have shown that LMP-420
inhibits several of the IFN-γ-induced chemokines such
as CXC chemokine ligand-9 (CXCL-9) and CXCL-10
(17). Based on these unique properties, we postulated
that administration of LMP-420 following ITx would be
beneficial in preventing damage to the islets and that
such treatment might synergize with a currently utilized
immunosuppressive regimen in prolonging islet allograft
survival. Our results demonstrate that administration of
LMP-420 significantly reduces early islet cell loss postTx leading to restoration of normoglycemia in chemically induced diabetic animals. We also demonstrate that
the beneficial effect of LMP-420 is mediated by its
potent anti-inflammatory and antiapoptotic pathways.
Furthermore, LMP-420 acts synergistically with the
commonly used immunosuppressive, calcineurin inhibitor cyclosporin A (CSA), to further enhance the survival
of allogeneic transplanted islets.
MATERIALS AND METHODS
Animals and Induction of Diabetes
Six- to 8-week-old C57BL/6 (H2b) and BALB/c
(H2d) mice were purchased from Jackson Laboratories.
Animal studies were performed in accordance with the
Animal Studies Committee, Washington University, St.
Louis, MO guidelines. Streptozotocin (STZ, Sigma, St.
Louis, MO, 200 mg/kg) was administered intraperitoneally (IP) to induce diabetes in C57BL/6 mice. Nonfasting blood glucose (NFBG) was measured using tail snip
(One Touch II-glucometer; Lifescan Inc., Milpitas, CA).
Mice with two consecutive NFBG ≥ 400 mg/dl were
considered diabetic.
Islet Isolation, Transplantation, and Treatment
Islets from murine pancreata were isolated by collagenase digestion and transplanted under the kidney
capsule as described previously (29). In brief, donor
pancreata were digested using collagenase-XI (Sigma, 4
mg/ml). Islets washed and purified on a Ficoll-gradient
were handpicked and cultured for 24 h before Tx. The
reversal of diabetes was defined as a reduction in consecutive NFBG <200 mg/dl post-ITx, and rejection was
defined as an increase in NFBG >250 mg/dl. LMP-420
(96–98%) was synthesized by Scynexis Inc. (Research
Triangle Park, NC). The LMP-420 and CSA stock solutions were made using 5% sorbitol (Sigma). The animals
were administered IP with either 5% sorbitol (n = 12) or
LMP-420 alone (25 mg/kg, n = 12) or CSA alone (25
mg/kg, n = 12) or a combination of LMP-420 and CSA
(both 25 mg/kg, n = 12) every day from day −1 of ITx.
Determination of Serum Insulin, Chemokines,
and Cytokines
The concentrations of insulin were measured using
an insulin ELISA (enzyme-linked immunosorbent assay)

kit (Mercodia Inc., Winston Salem, NC). Serum
obtained (stored at −20°C) from 60–80 µl blood collected by retro-orbital puncture was used. Standard insulin solution and serum (25 µl) were added into a
monoclonal anti-insulin antibody (Ab)-coated ELISA
plate along with enzyme conjugate and incubated for 2
h at room temperature. After washing six times, TMB
(3,3′,5,5″-tetramethylbenzidine) substrate (200 µl) was
added and incubated for another 5 min. The reaction was
stopped by adding 50 µl of stopping solution and read
at 450 nm on a microplate reader.
Serum levels of cytokines were analyzed using a multiplex bead immunoassay (Biosource International Inc.,
Camarillo, CA) as per the manufacturer’s protocol (10).
Briefly, primary Ab-coated beads with standards and samples were incubated for 2 h at room temperature. The
wells were washed and incubated with biotinylated Abs
for 30 min. The streptavidin-R-phycoerythrin solution
was added and read using the Luminex-xMAP-system.
Analysis of T-Cell Frequency
Transplanted mice splenocytes were stimulated with
irradiated donor splenocytes; the number of T cells
secreting IFN-γ, IL-10, IL-4, and TNF-α was enumerated by ELISPOT (Enzyme-linked immunosorbent spot)
(5). Briefly, Millipore MultiScreen filter plates (Millipore Corporation, Billerica, MA) were coated overnight
with 5 µg/ml capture mouse cytokine-specific mAb (BD
Biosciences PharmingenTM, San Diego, CA). Subsequently, 3 × 105 recipient splenocytes were cultured in
triplicate in the presence of irradiated donor splenocytes
(1:1 ratio). After 48–72 h, 2 µg/ml biotinylated mAb
was added to the wells and incubated overnight. The
plates were washed and 100 µl streptavidin-horseradish
peroxidase (HRP) was added. After 2 h, the assay was
developed by 3-amino-9-ethylcarbazole substrate reagent
and the spots were analyzed.
Immunohistochemistry for Graft-Infiltrating CD4+
and CD8+ T Cells
Explanted kidneys containing transplanted islets were
embedded in frozen tissue matrix and sections cut at a
6-µm thickness. They were fixed in cold alcohol for 2
min (−20°C), air dried, treated with 3% H2O2, and
blocked with biotin/avidin (Avidin/Biotin Blocking Kit;
Vector Laboratories, Burlingame, CA). The sections
were incubated overnight with rat anti-mouse mAbs
against cluster of differentiation 4 (CD4) and CD8 T
cells (5.0 µg/ml, BD Biosciences PharmingenTM) or isotype Ab (Chemicon International, Billerica, MA).
Washed sections were treated with biotin-conjugated
goat anti-rat IgG followed by streptravidin-HRP. The
presence of positive cells was detected with the DAB
(3,3′-diaminodbenzidine) substrate kit (BD Biosciences
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PharmingenTM). Photomicrographs were taken of 10 random field stained sections using a Nikon Eclipse 50i
microscope (10×) from each group and were analyzed
using morphometric software (NIS-Elements BR 3.2
program) in a blinded fashion. Sections were also prepared from control islet grafts from nontreated mice
with and without incubation with mouse CD4+ and
CD8+ Abs.
Determination of SOCS-1 and Mn-SOD by RT-PCR
and Western Blots
A significant portion of pancreatic islet grafts can be
destroyed by apoptosis, failing to engraft in the early
period immediately post-ITx. Overexpression of suppressor of cytokine signaling-1 (SOCS-1) and manganese-dependent superoxide dismutase (Mn-SOD) in islet
grafts achieve an antiapoptotic effect to prolong graft
survival. Expression profiles of SOCS-1, Mn-SOD, and
actin were analyzed by FAM-labeled RT-PCR primers
(Applied Biosystems, Foster City, CA). Briefly, total
RNA was extracted from islet grafts using TRIzol
reagent. The RNA was reverse transcribed and real-time
RT-PCR was performed using iCycler 480 Probes Master (Bio-Rad Laboratories, Inc., Hercules, CA). Cycling
conditions consisted of an initial denaturation of 95°C
for 15 min, followed by 40 cycles of 95°C for 30 s,
followed by 61°C for 1 min.
Protein levels of SOCS-1 and Mn-SOD were analyzed by Western blot. The graft extracts were obtained
using 4% SDS cell lysis buffer containing protease
inhibitor cocktail. Extracts were boiled for 20 min in
sample buffer [200 mmol/L Tris (pH 6.8), 20% glycerol,
2% SDS, 0.1% bromophenol blue, and 10% β-mercaptoethanol], centrifuged for 30 min, and run on 4–12% gradient Bis-Tris denaturing gels (NuPage; Invitrogen).
The gels were transferred onto nitrocellulose membranes, and blocked overnight with 5% nonfat milk in
PBS-T (0.1% Tween20). Thereafter, the membranes
were incubated for 1 h with the appropriate Abs. After
labeling with HRP-labeled secondary Ab (1:10,000 dilution; Jackson ImmunoResearch Laboratory Inc., West
Grove, PA), the membranes were developed using
chemiluminescence detection kit (Millipore) and analyzed using Bio-Rad Universal Hood-II (Bio-Rad Laboratories, Inc.). Morphometric analysis was performed
using the software provided by the company.
Detection of Donor-Specific Abs (DSA) in the
Recipient’s Sera by Immunofluorescence
Sera from sensitized C57BL/6 mice were assayed for
allo-Abs by their ability to bind BALB/c splenocytes
using flow cytometry. Donor splenocytes (0.5 × 106)
were incubated in 50 µl fluorescence-activated cell sorter (FACS) buffer (5% FBS, 1% HEPES, 0.2% sodiumazide in HBSS), containing 1:10 recipient serum for 30
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min at 4°C. Anti-mouse phycoerythrin (PE)-labeled secondary Ab was added and further incubated for 30 min.
The cells were then washed and read on a fluorescenceactivated cell sorter (FACS) caliber machine with instrumental settings for mouse splenocytes.
Statistical Analysis
Data are expressed as mean ± SD. Statistical differences between means were analyzed using a paired or
unpaired Student’s t-test, or subjected to Scheffe’s post
hoc test in analysis of variance (ANOVA). Using the
Scheffe procedure all possible comparisons between the
means of controls with individual treatment groups (LMP420 alone, CSA alone, and LMP+CSA group) were conducted. A value of p < 0.05 was considered significant.
RESULTS
LMP-420 and CSA Prolongs Islet Allograft Survival
To determine the effect of LMP-420, diabetic
C57BL/6 mice were treated with LMP-420 1 day prior
to ITx (500 BALB/c islets) and daily thereafter. As
shown in Figure 1, LMP-420 significantly prolonged
islet allograft survival (22 ± 3 days), whereas the vehicle-treated cohort rejected the allograft on 7 ± 2 days
post-Tx (p = 0.005). To confirm that normoglycemia
was achieved by the transplanted islets, a group of LMP420-treated mice was nephrectomized 14 days post-ITx.
Nephrectomy resulted in prompt elevation of NFBG levels, demonstrating that normoglycemia was being
achieved by the transplanted islets (Fig. 1A). Daily
administration of CSA also significantly prolonged graft
survival (24 ± 3 days) compared with control (p =
0.001) (Fig. 1B). These results demonstrate that LMP420 prolongs islet allograft survival similar to that
observed with CSA.
Synergism of LMP-420 With Low-Dose CSA
in Prolonging Islet Allograft Survival
The above results demonstrated that either LMP-420
or CSA alone significantly prolonged islet allograft survival. However, islets were rejected between days 23
and 27 post-Tx, respectively. Therefore, we sought to
determine whether LMP-420 could act synergistically
with CSA to prolong allograft survival. Combined treatment (LMP+CSA) significantly prolonged allograft survival (35 ± 5 days; p = 0.0001) compared to control
(Fig. 1B). These results demonstrate that combination of
the anti-inflammatory LMP-420 with immunosuppressive agents such as calcineurin inhibitors can result in
enhanced islet graft survival. Furthermore, the sera from
the control cohort had significantly lower (p = 0.0002)
(Fig. 2A) insulin on day 8 compared with all three treatment cohorts (LMP, CSA, or LMP+CSA). All three
treatment regimens demonstrated insulin levels up to
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Figure 1. Effect of administration of LMP-420 (A), cyclosporin A (CSA), and LMP+CSA (B) on islet allograft survival. Diabetic
C57BL/6 mice were transplanted (Tx) with 500 BALB/c islets. LMP-420 (25 mg/kg), CSA (25 mg/kg), and LMP+CSA (25 mg/
kg each) were administered by IP injection daily from day −1. Nonfasting blood glucose (NFBG) levels were monitored twice a
week by glucometer utilizing a tail snip method. Data represents mean ± SD for n = 12.

0.5 ± 0.1 pg/ml from day 8 through day 20. Additionally, serial histology sections of transplanted islets from
treatment groups showed positive staining for insulin on
day 8, signifying the presence of functionally healthy
islets (Fig. 2B). Insulin levels in LMP-420 and CSA

treatment cohorts reached pre-Tx levels by day 22, indicating the rejection. In contrast, the combined treatment
cohort retained high serum insulin levels at 32 days
post-Tx, corresponding to the graft survival curve
(Fig. 1B).

Figure 2. Determination of insulin content in islet allograft recipient’s serum by insulin ELISA. Sera (25 µl) were added to
monoclonal anti-insulin Ab-coated ELISA plates (Mercodia Inc., Winston Salem, NC) with enzyme conjugate and incubated for 2
h. After washing (6×), they was incubated with TMB substrate (200 µ) for 5 min. After adding 50 µl of stopping solution the plate
was read at 450 nm. (B) Average numbers of insulin-positive [anti-mouse fluorescein isothiocyanate (FITC) Abs] cells in serial
histology sections of explanted grafts from control, LMP-420, CSA, and LMP+CSA treatment cohorts on day 8 post-Tx, respectively (**p < 0.01).
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LMP-420, CSA, and LMP+CSA Administration Delay
the Infiltration of Donor-Specific CD4+ and CD8+ Cells
Into the Islet Grafts
To identify the kinetics and specificity of cells infiltrating the islet allografts, we performed immunohistology of the grafts on day 8 post-Tx, a time point when
controls start rejecting. Grafts from normoglycemic
mice were removed from all three treatment cohorts and
sections were stained for CD4+ and CD8+ cells. As
shown in Figure 3, the control grafts showed marked
infiltrating CD4+ and CD8+ cells (152 ± 42 and 224 ± 51
cells, respectively, p = 0.0001) enumerated by morphometric analysis using NIS-Elements BR 3.2 software. In
contrast, the LMP-420 and CSA groups had 42 ± 20,
58 ± 30 and 76 ± 24, 112 ± 42 CD4+ and CD8+ cells,
respectively, which though reduced was not very significantly different from controls. In contrast, infiltrations of CD4+ and CD8+ cells (22 ± 10 and 31 ± 18
cells, respectively) following combined treatment with

Figure 3. Immunohistochemical staining for graft infiltrating
T cells. Cryosections of islet grafts from mice on day 8 postTx were stained with rat mAbs specific to mouse CD4+ and
CD8+ T cells. The secondary biotinylated goat anti-rat Ab was
added followed by streptavidin-HRP and developed using
DAB substrate. Pictures taken (10×; Nikon Eclipse 50i microscope) were used for morphometric analysis using NIS-Elements BR 3.2 program. The data represents mean ± SD (**p
< 0.01).
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LMP+CSA were significantly decreased compared to
control (p = 0.0007) as well as LMP-420- or CSAtreated cohorts (p = 0.004). These results demonstrate
that the infiltration of T cells into the allograft was significantly reduced when LMP-420 is combined with
CSA, which agrees with the prolonged islet allograft
survival noted with this regimen.
Administration of LMP-420 or CSA and Combined
Treatment Leads to Decreased Production
of Proinflammatory Mediators
Ischemia-reperfusion injury results in increased production of proinflammatory cytokines that accelerate
islet cell death (5,13). To test whether LMP-420, CSA,
and the combination decreases the levels of inflammatory cytokines and chemokines, sera collected from all
four groups on day 8 post-Tx were analyzed using a
Mouse Twenty-plex Luminex kit. As shown in Figure
4A, cytokines IL-1β and IL-4 were 1.3- to 2-fold lower
in all three treatment cohorts compared to control (p =
0.01). Furthermore, the T-cell proliferative cytokine IL2 was 2.5- to 3-fold lower in the CSA and LMP+CSA
cohorts (p = 0.01) but not in the LMP-420 treatment
cohort compared to control (144 ± 18 vs. 178 ± 21 pg/
ml, p = 0.145). In contrast, serum IL-10 levels in the
LMP-420 treatment cohort were 2.5-fold (221 ± 9.8 vs.
86 ± 14.3 pg/ml, p = 0.0001) and 1.6-fold (221 ± 9.8 vs.
136 ± 18 pg/ml, p = 0.004) higher than those in the
control and CSA administered mice, respectively. Furthermore, the LMP+CSA group had 3-fold higher concentrations of IL-10 in their sera compared to controls
(86 ± 14.3 vs. 240.6 ± 35 pg/ml, p = 0.00001), indicating a potentially significant role for LMP-420 in increasing IL-10-mediated anti-inflammatory effects. Additionally,
LMP-420 alone and LMP+CSA cohorts had 3- and 2fold reductions of TNF-α, respectively, in their sera
compared with the control cohort (p = 0.001). The CSA
alone-treated group also showed a decrease in TNF-α
concentration (372.3 ± 47 vs. 284.3 ± 27 pg/ml, p <
0.05) compared to controls.
Chemokines produced after Tx play a pivotal role in
recruitment of inflammatory cells (25). To determine the
effect of LMP-420 on chemokine production, sera were
analyzed for the levels of chemokines that play critical
roles in directing mononuclear cells to islet allografts
(48). As depicted in Figure 4B, LMP-420 and
LMP+CSA decreased the levels of IFN-γ-inducible protein-10 (IP-10), monocyte chemotactic protein-1 (MCP1), and macrophage inflammatory protein (MIP) by
1.5- to 2.9-fold (p < 0.001) compared to control. In contrast, there was no significant difference in the concentrations of the above chemokines between control and
CSA cohorts. In addition, the concentrations of chemokines keratinocyte chemoattractant (KC) and monokine
induced by IFN-γ (MIG) were found to be significantly
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Figure 4. Analysis of cytokines and chemokines in transplanted mouse sera by Luminex. Sera
collected on day 8 post-Tx were used for comparative screening of various cytokine levels using
a Luminex kit according to the protocol provided by the company. The data are representative of
three separate experiments done in triplicate, and the SD bars are illustrated for the Luminex assay
(*p < 0.05, **p < 0.01).

less (1.6- to 2.5-fold, p < 0.001) in all LMP-420, CSA,
and LMP+CSA treatment groups compared to controls.
Low Frequency of Donor Reactive T-Cells
in the Recipient Spleen After Treatment
With LMP-420, CSA, and LMP+CSA
To study the effect of treatment with the above agents
on the initiation of alloimmune responses after ITx, we
determined the frequency of IL-4-, IL-10-, IFN-γ-, and
TNF-α-secreting T cells upon stimulation with donor
cells by ELISPOT on day 8 post-Tx (Fig. 5). We
observed 2.3-, 2-, and 4.1-fold reductions (p < 0.001) in
the frequency of IL-4-producing T cells in LMP-420,
CSA, and LMP+CSA compared with controls, respectively (Fig. 5A). Similarly, the IFN-γ-producing T-cell
frequency was reduced by 1.6-, 2.0-, and 2.9-fold (p <
0.001) compared with control, respectively (Fig. 5C).
The frequency of TNF-α-producing T cells in LMP-420
and LMP+CSA administered mice was 3-fold less (p <

0.01), whereas the CSA alone group demonstrated a 1.3fold decrease (p < 0.05) (Fig. 5D). In contrast, LMP420, CSA, and LMP+CSA groups had 2-, 1.4-, and
2.4-fold increases in the frequency of IL-10-producing
T cells, respectively (Fig. 5B), compared to controls.
These ELISPOT results correlated well with the
decreased levels of proinflammatory and increased levels of anti-inflammatory cytokines in the sera of treatment cohorts.
Enhanced SOCS-1 and Mn-SOD Levels With LMP
and CSA Combination
The results presented above indicated enhanced production of anti-inflammatory molecules after treatment
with LMP-420 and CSA. To further determine the
potential mechanisms involved in prolonged allograft
survival, we analyzed for the expression of SOCS-1 and
Mn-SOD, two important molecules involved in the prevention of islet apoptosis. Mn-SOD is a mitochondrial
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antioxidant enzyme, increased expression of which protects islet cells from inflammatory damage (19). The
transcription factor SOCS-1 has the ability to negatively
regulate inflammatory cytokine signaling and can also
inhibit islets apoptosis through suppression of the Janus
kinase-signal transducer and activator of transcription
(JAK-STAT) pathway (23). The effect of combined
treatment with LMP+CSA on the intracellular expression of these molecules was determined using both
Western blot and RT-PCR analyses of explanted grafts
on day 8 post-Tx. As shown in Figure 6A and B, Western blot and densitometry analysis clearly demonstrated
that there are 2.8 ± 0.6- and 1.6 ± 0.4-fold increases in
the levels of SOCS-1 and Mn-SOD (p < 0.001) in allografts from LMP-420-treated mice. Furthermore, the
LMP+CSA demonstrated a very significant 6.2 ± 0.6and 4.3 ± 0.5-fold increase of SOCS-1 and Mn-SOD
levels, respectively (p < 0.0001). RT-PCR analysis of
mRNA expression levels of SOCS-1 and Mn-SOD in
treatment cohorts also demonstrated enhanced expression of these transcription factors (11.8 ± 3.1 and 6.8 ±
2.1, respectively) with coadministration over LMP-420
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alone (4.3 ± 1.1 and 3.2 ± 0.5, respectively) (Fig.6C, D).
In addition, blinded morphometric analysis of the
explanted islet grafts (day 8) upon terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining
demonstrated 3.2-fold (12 ± 7 vs. 47 ± 13 cells)
decreased numbers of apoptotic cells in LMP+CSA
treatment group (data not shown) compared to the control, respectively. These results further support that
LMP-420 induces upregulation of the antiapoptotic and
anti-inflammatory transcriptional factors Mn-SOD and
SOCS-1, which is beneficial for the continued function
of transplanted islets.
LMP-420, CSA, and LMP+CSA Administration Delay
Formation of Abs to Donor Major Histocompatibility
Complex (MHC) (DSA) in the Recipient
Even after continued treatment with LMP-420 and
LMP+CSA allograft rejection occurred at 23 and 35
days post-Tx, respectively. Studies from our laboratory,
and others, have shown that the development of DSA
correlates with the rejection of transplanted islets (6,29).
Therefore, sera collected at the time when glucose levels

Figure 5. Determination of frequency of donor-specific T cell by ELISPOT. Recipient (C57BL/6) splenocytes (3 × 105) isolated
on day 8 post-Tx from treated and control cohorts were stimulated with irradiated donor (BALB/c) splenocytes (3 × 105) and
analyzed for production of interleukin (IL)-4 (A), IL-10 (B), interferon-γ (IFN-γ) (C), and tumor necrosis factor-α (TNF-α) (D).
The data are representative of three separate experiments performed in triplicate, and SD bars are illustrated for these assays (*p <
0.05, **p < 0.01).
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were rising were analyzed for development of DSA by
FACS. The sera of mice treated with LMP-420 or CSA
alone showed DSA on day 22 post-Tx (Fig. 7A, B). This
paralleled the increase in NFBG and decreased insulin
levels, indicating rejection of transplanted islets. In contrast, LMP+CSA-treated sera showed no Abs binding to
the donor splenocytes on day 22 (Fig. 7C), with both
normoglycemia and insulin levels significantly higher,
indicating functional islets. However, the presence of
DSA was detected on day 33, when all the mice became
hyperglycemic (Fig. 7D). These results indicate that combined treatment of LMP-420 with CSA can not only downregulate the cellular immune recognition of the graft but
also delay the humoral response against the graft.
DISCUSSION
Islet transplants are subjected to ischemia and reperfusion injuries as a consequence of both their isolation
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and Tx procedures (4,22,38). Prior to vascularization,
transplanted islets are susceptible to inflammation and
apoptosis due to lack of nutrition and compromised
blood flow. Furthermore, the processes of coagulation
and thrombosis contribute to multiple insults suffered by
the islets during early post-Tx period (38). These factors
induce inflammation, apoptosis, and loss of islets, subsequently inducing adaptive immune responses that compromise the long-term survival. It is estimated that up to
70% of the islets are lost in the early post-Tx period,
contributing to the need for islets from multiple pancreata to achieve insulin independence in a single recipient (2). Interest in clinical ITx has contributed to
development of improved harvesting, purification procedures, and new steroid-free immunosuppressive drug
regimens that minimize β-cell toxicity and insulin resistance (45). This has resulted in excellent rates of engraftment and achievement of normoglycemia. Nonetheless,

Figure 6. RT-PCR and Western blot analysis of SOCS-1 and Mn-SOD with LMP-420 and CSA treatment. (A) Western blot
analysis of suppressor of cytokine signaling-1 (SOCS-1) and manganese-dependent superoxide dismutase (Mn-SOD) on the explanted islets grafts obtained on day 8 post-Tx. Islets grafts were lysed with lysis buffer and the cytoplasmic extracts from all four
cohorts were analyzed for SOCS-1 and Mn-SOD proteins using mAbs. (B) Densitometric analysis of the protein expression (gray
bars represent SOCS-1 and hatched bars represent Mn-SOD). (C, D) RT-PCR on the mRNA extracts of the explanted islets was
performed for SOCS-1 and Mn-SOD, respectively, expression using FAM-labeled primers. Data are from four different experiments
and mean ± SD is reported.
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Figure 7. Analysis of donor-specific antibodies (DSA) in recipient sera by fluorescence-activated
cell sorter (FACS). Donor splenocytes (5 × 105) were incubated in 50 µl FACS buffer containing
1:10 dilution of recipient serum for 30 min at 4°C. Phycoerythrin (PE)-labeled secondary Ab was
added and further incubated for 30 min. The cells were washed three times with FACS buffer and
read on FACS caliber machine with instrumental setting for mouse splenocytes. (A–C) LMP-420,
CSA, and LMP+CSA on day 22. (D) LMP+CSA on day 33.

recent longer term follow-up data of ITx recipients have
shown that most recipients who are rendered free from
insulin therapy at 1 year need to reinstitute insulin therapy within 5 years post-Tx (42).
Traditionally, CSA is an immunomodulator that is
effectively utilized to prevent rejection in solid organ Tx
such as heart, liver, and kidney (3,9,12). It has a high
specificity for T lymphocytes and inhibits cell-mediated
immune responses. We previously identified a novel
small molecule, LMP-420, which effectively inhibits
TNF-α production both in vitro and in vivo (17). In our
current study using a murine model of ITx we demonstrate that a combination of LMP-420 with low-dose
CSA results in enhanced islet engraftment resulting in
significant prolongation of islet allograft function. This
enhanced engraftment is a result of both downregulation
of proinflammatory cytokines/chemokines and upregulation of anti-inflammatory cytokines/chemokines. More
importantly, this combined treatment results in the

upregulation of both the transcriptional and protein levels of SOCS-1 and Mn-SOD, two molecules previously
demonstrated to be important in allograft survival (11,24).
Initial insult to β-cells following the Tx reduces their
functional efficiency. In our murine model, animals continually treated with LMP-420 and CSA showed better
islet allograft survival as evidenced by continued normoglycemia and increased serum insulin levels (Figs. 1
and 2). Proinflammatory cytokines have been shown to
play a significant role in acute graft rejection. Pascher
et al. (33) demonstrated that anti-TNF therapy attenuated the acute rejection episode. Studies have shown that
the local expression of the inflammatory cytokine TNFα can impair tolerance to both auto- and alloreactivity
(46). Endogenous overexpression of TNF-α resulted in
accelerated rejection of transplanted islets in both autoimmune and chemically induced diabetic mice, compared to wild-type, by accelerating the infiltration of
CD4+ and CD8+ T cells (34). Our results demonstrate
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(Fig. 3) reduced infiltration of both CD4+ and CD8+ T
cells by 70% on day 8 following administration of LMP420 alone. However, coadministration of LMP-420 and
CSA reduced the T-cell infiltration by 95%. This
decreased cellular infiltration and significantly decreased
serum TNF-α noted following administration of LMP420 indicated that these mechanisms play an important
role in the noted prolongation of islet allografts following LMP-420 administration.
The role of proinflammatory responses in graft rejection is well defined (1,26). T cells are important in the
pathogenesis of rejection, and constitute a predominant
infiltrating cell type. However, other mononuclear cell
subpopulations, including B cells, natural killer (NK)
cells, and monocytes/macrophages also have been shown
to contribute in rejection (37,39). Proinflammatory cytokines/chemokines released from the initial infiltrating
cells plays a major role in the continued infiltration of
cells to the graft (5,20,25,49). In this study we demonstrated that LMP-420 not only attenuates proinflammatory TNF-α, IL-1β, and MCP-1 responses, but also
augments an anti-inflammatory IL-10 response (Fig. 4).
We also demonstrated that the combination of LMP-420
and CSA provided a synergistic effect on the cytokine
environment that facilitated islet allograft survival.
Thus, our results demonstrated that the delayed islet
allograft rejection is due to a skewing of the equilibrium
towards an enhanced IL-10 with decline in proinflammatory cytokines including TNF-α, IL-1β, IL-2, and
IL-4. Based on our data, we conclude that regulatory
mechanisms were induced by LMP-420, which inhibits
the proinflammatory TNF-α and simultaneously turns
on the anti-inflammatory IL-10. A similar reduction in
proinflammatory cytokine responses following administration of LMP-420 has been reported by Haraguchi
et.al. (18) for the potential use of this agent to treat
HIV patients.
Various studies demonstrate that TNF-α causes
decreased expression of Mn-SOD and SOCS-1, both of
which are known to reduce TNF-α-induced apoptotic
effect of caspases (15,23,35). Suo et al. have demonstrated that SOCS-1 inhibits apoptosis in islet grafts
through caspase 3-dependent and apoptosis-inducing
factor caspase-independent pathways (47). In animal
models inactivation of Mn-SOD has been correlated
with Tx rejection in cardiac (32) and renal (36) allografts. In our current study, we demonstrate that LMP420 downregulates chemokines down stream of TNF-α
signaling, resulting in enhanced expression of Mn-SOD
(1.6 ± 0.4-fold) and SOCS-1 (2.8 ± 0.6-fold). These data
clearly demonstrate the antiapoptotic effect of LMP-420,
which is crucial for the enhanced survival and functionality of Tx islets.
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Previous studies from our laboratory, and studies by
others, have demonstrated that Abs to HLA in human
ITx has a positive correlation with graft rejection
(8,27,40). Studies in animal models of ITx also indicate
that Tx across sensitization to major histocompatibility
(MHC) antigens is unfavorable towards islet allograft
survival and function (6). Earlier studies in our laboratory demonstrated that ITx into MHC-mismatched STZtreated diabetic mice resulted in the rejection of islets
with mean survival time 2 days when compared to
unsensitized mice with mean survival time of 10 days
(16). In our current report, we demonstrate that the
enhanced protection and survival is also evidenced by
delayed circulating levels of DSA in the cotreatment
cohort. FACS analysis demonstrated appearance of DSA
during the rejection (22 days post-Tx) in LMP-420 and
CSA alone groups while no DSA was detected in serum
from cotreatment mice. The serum DSA development
was detected during the final stages of graft rejection
(35 days post-Tx), indicating that combined treatment
not only downregulates cellular immune response but
also delays the humoral immune response against the graft.
Our results conclusively demonstrate that LMP-420
has a potent anti-inflammatory and antiapoptotic effect.
LMP-420 has been further demonstrated to enhance islet
survival and function by inhibiting the alloimmune
humoral and cellular responses. Based on our data, we
propose a novel therapeutic application for LMP-420 in
combination with current therapeutic regimens using
calcineurin inhibitors, such as CSA, in the amelioration
of rejection following human islet transplantation.
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